198 related articles for article (PubMed ID: 25858582)
21. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F
Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218
[No Abstract] [Full Text] [Related]
22. Bone marrow leukaemic transformation of myelodysplastic syndrome revealed by a cutaneous Langerhans cell infiltrate: partial response to azacitidine.
Osio A; Elfatoiki F; Raffoux E; Vignon-Pennamen MD; de Labarthe A; Cordoliani F; Petrella T; Bagot M; Janin A; Battistella M; Bouaziz JD
Eur J Dermatol; 2013; 23(5):710-1. PubMed ID: 24125873
[No Abstract] [Full Text] [Related]
23. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.
He PF; Zhou JD; Yao DM; Ma JC; Wen XM; Zhang ZH; Lian XY; Xu ZJ; Qian J; Lin J
Oncotarget; 2017 Jun; 8(25):41498-41507. PubMed ID: 28489568
[TBL] [Abstract][Full Text] [Related]
24. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G
Leukemia; 2012 May; 26(5):1106-7. PubMed ID: 22124213
[No Abstract] [Full Text] [Related]
25. Azacitidine in AML: a treatment option?
Huls G
Blood; 2015 Jul; 126(3):283-4. PubMed ID: 26185114
[TBL] [Abstract][Full Text] [Related]
26. Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and peripheral-blood monocytosis.
Dey BR; Spitzer TR; Hasserjian RP
N Engl J Med; 2009 Sep; 361(11):1099-106. PubMed ID: 19741232
[No Abstract] [Full Text] [Related]
27. Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Stone A; Zukerman T; Flaishon L; Yakar RB; Rowe JM
Leuk Res; 2019 Jul; 82():36-42. PubMed ID: 31152922
[TBL] [Abstract][Full Text] [Related]
28. BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.
Lazarini M; Machado-Neto JA; Duarte AD; Pericole FV; Vieira KP; Niemann FS; Alvarez M; Traina F; Saad ST
Haematologica; 2016 Nov; 101(11):e445-e448. PubMed ID: 27443286
[No Abstract] [Full Text] [Related]
29. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
[TBL] [Abstract][Full Text] [Related]
30. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
[No Abstract] [Full Text] [Related]
31. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.
Sekeres MA; Steensma DP
J Clin Oncol; 2012 Nov; 30(33):4061-3. PubMed ID: 23008302
[No Abstract] [Full Text] [Related]
32. Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine.
Mulay S; Bauer F; Boruchov A; Bilgrami S
Leuk Lymphoma; 2011 Feb; 52(2):341-3. PubMed ID: 21142783
[No Abstract] [Full Text] [Related]
33. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network.
Bories P; Bertoli S; Bérard E; Laurent J; Duchayne E; Sarry A; Delabesse E; Beyne-Rauzy O; Huguet F; Récher C
Am J Hematol; 2014 Dec; 89(12):E244-52. PubMed ID: 25195872
[TBL] [Abstract][Full Text] [Related]
34. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
Singh SN; Cao Q; Gojo I; Rapoport AP; Akpek G
Bone Marrow Transplant; 2012 Jul; 47(7):1008-9. PubMed ID: 22080965
[No Abstract] [Full Text] [Related]
35. Decitabine in older adults with acute myeloid leukemia: why was the dream broken?
Kantarjian H; Wilson W; Ravandi F; Estey E
J Clin Oncol; 2013 May; 31(14):1795-6. PubMed ID: 23547076
[No Abstract] [Full Text] [Related]
36. Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.
Yamamoto R; Yokoyama A; Yoneda M; Ohashi K; Hosoda T; Kagoo T; Boku S; Ueno H; Yano T
Ann Hematol; 2014 Dec; 93(12):2081-2. PubMed ID: 24863693
[No Abstract] [Full Text] [Related]
37. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
38. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.
Pinto A; Zagonel V; Attadia V; Bullian PL; Gattei V; Carbone A; Monfardini S; Colombatti A
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():28-32. PubMed ID: 2483349
[No Abstract] [Full Text] [Related]
39. The role of hypomethylating agents in the treatment of elderly patients with AML.
Al-Ali HK; Jaekel N; Niederwieser D
J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
